Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: To investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of multiple oral doses of the dipeptidyl peptidase‐4 (DPP‐4) inhibitor linagliptin (BI 1356) in patients with type 2 diabetes mellitus. Methods: Forty‐seven male type 2 diabetic patients received linagliptin 1, 2.5, 5 or 10 mg, or placebo, once daily for 12 days. Results: Linagliptin exposure [area under the plasma concentration–time curve and maximum plasma concentration ( C max )] increased less than proportionally with dose. Accumulation half‐life was short (8.6–23.9 h), resulting in rapid attainment of steady state (2–5 days) and little accumulation (range: 1.18–2.03). The long terminal half‐life (113–131 h) led to a sustained inhibition of DPP‐4 activity. Renal excretion was below 1% on day 1 in all dose groups. Inhibition of plasma DPP‐4 activity correlated well with linagliptin plasma concentrations, resulting in DPP‐4 inhibition >90% in the two highest dose groups; even 24 h postdose, DPP‐4 inhibition was >80%. Following an oral glucose tolerance test, 24 h after the last dose, statistically significant reductions of glucose excursions were observed with linagliptin (2.5, 5 and 10 mg doses) compared with placebo. Linagliptin was well tolerated. The frequency of adverse events (AEs) was not higher with linagliptin (54%) than with placebo (75%). No serious AEs and no episodes of hypoglycaemia were reported. Conclusions: In type 2 diabetic patients, multiple rising doses of linagliptin were well tolerated and resulted in significant improvements of glucose parameters. Together with the favourable pharmacokinetics, these results confirm the unique profile of linagliptin in the DPP‐4 inhibitor class.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Kramer, H. J. (2003) · JAMA · doi:10.1001/jama.289.24.3273 · Cited by 618
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Cited by
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Del Prato, S., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. ‐., & Dugi, K. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 299
Self-citationTaskinen, M. ‐., Rosenstock, J., Tamminen, I., Kubiak, R., Patel, S., Dugi, K. A., & Woerle, H. ‐. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01326.x · Cited by 294
Self-citationPharmacokinetics of dipeptidylpeptidase‐4 inhibitors
Scheen, A. J. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01212.x · Cited by 281
Metadata
- Authors
- Heise, T., Graefe‐Mody, E. U., Hüttner, S., Ring, A., Trommeshauser, D., & Dugi, K. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-06-26
- Volume
- 11
- Issue
- 8
- Pages
- 786-794
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2118186702
- Cited by
- 175
- References
- 5
- FWCI
- 18.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01046.x
- The paper
- Heise, T., Graefe‐Mody, E. U., Hüttner, S., Ring, A., Trommeshauser, D., & Dugi, K. A. (2009). Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01046.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.